Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden.

Amanda Hansson HedblomChrissy AlmondFredrik BorgströmIndeg SlyDana EnkussonAnders Troelsgaard BuchholtLinda Karlsson

Published in: Cost effectiveness and resource allocation : C/E (2018)

Results indicate ustekinumab dominates adalimumab in conventional care failure population, and is cost-effective versus vedolizumab in TNF-alpha-inhibitor failure population.

Keyphrases

rheumatoid arthritis
healthcare
ulcerative colitis
palliative care
early onset
high intensity